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Abstract 32 
 33 
Prognosis for unresectable canine malignant melanoma (MM) is typically poor, and 34 
therapeutic approaches remain largely palliative. A bi-institutional trial was conducted 35 
to compare efficacy and safety of radiotherapy (RT) and RT with post-radiation 36 
temozolomide in dogs with chemotherapy-naïve, measurable MM. RT consisted of 37 
5x6 Gy fractions over 2.5 weeks. Dogs whose owners wished to pursue 38 
chemotherapy received adjuvant oral temozolomide (60 mg/m2 for 5 days every 28 39 
days). Fifteen dogs were treated with RT only (Group 1) and 12 dogs subsequently 40 
received temozolomide (Group 2). Overall response rate was similar between Group 41 
1 (86.7%) and Group 2 (81.1%). Median time to progression (TTP) was significantly 42 
longer in Group 2 (205 days) compared to Group 1 (110 days; p=0.046). Survival 43 
time was not significantly different between groups. Both treatments were well 44 
tolerated. Post-radiation temozolomide has a good safety profile, and may improve 45 
TTP in MM when compared to conventionally fractionated RT.  46 
 47 
  48 
 3 
Introduction 49 
 50 
In dogs, malignant melanoma (MM) has historically been considered an extremely 51 
aggressive tumor with a high degree of local invasiveness and high metastatic 52 
propensity,1 and is comparable to the human counterpart.2 53 
While loco-regional tumor control can be achieved by means of surgery with or 54 
without radiation therapy (RT), the high metastatic potential hinders long-term control, 55 
ultimately leading to death.3-5 56 
Systemic treatment of canine malignant melanoma remains suboptimal, with little 57 
evidence that chemotherapy improves survival time. Response rates to platinum 58 
compounds have traditionally been no better than 18% to 28%.6,7 Furthermore, 59 
complete responses (CR) are rare and short in duration (3 to 5 months).6,7 Overall, 60 
the reported long-term survival rate of canine melanoma is not encouraging due to its 61 
chemo-resistance and rapid metastasis. Furthermore, platinum compounds may 62 
cause renal and gastrointestinal toxicity, and are generally reserved for dogs with 63 
good organ function.6,7 64 
Immunotherapy targeting the melanoma differentiation antigen tyrosinase has been 65 
recently explored as a strategy for the systemic treatment of canine melanoma, with 66 
contradictory results.8,9 The combination of surgery with or without RT and the 67 
Oncept vaccine initially showed promise as superior to loco-regional treatment alone 68 
in the treatment of stage II-III canine MM,8 until more recent studies revealed 69 
equivalent survival.9 70 
Better tolerated, less toxic, and more efficacious treatments for this disease are 71 
needed. Also, because chemotherapy remains palliative, any improvement in 72 
tolerability or ease of treatment delivery is desirable. 73 
 4 
 74 
Temozolomide, an oral alternative to the alkylating agent dacarbazine, is orally 75 
bioavailable, has greater ease of administration and lower toxicity, and has clinical 76 
activity against human melanoma equivalent to dacarbazine.10-13 Another advantage 77 
of temozolomide over dacarbazine is its ability to undergo spontaneous conversion to 78 
the highly reactive metabolite 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide 79 
without requiring any metabolic activation. Similar to dacarbazine, temozolomide also 80 
has the ability to cross the blood-brain-barrier, and may therefore play a role in 81 
treating patients with brain metastases from melanoma.14,15 Finally, temozolomide 82 
has been shown to have radioenhancing activity in certain tumor types such as 83 
glioblastoma.13,16 84 
In veterinary oncology, temozolomide has only been evaluated in dogs with 85 
lymphoma, where the combination of temozolomide and doxorubicin proved to be 86 
well tolerated and active.17 87 
 88 
Aim of this prospective, controlled, non-randomized, bi-center clinical trial was to 89 
investigate objective response rate and time to progression (TTP) (primary 90 
objectives), as well as overall survival (OS) and safety profile (secondary objectives) 91 
of RT in comparison with RT and temozolomide in dogs with chemotherapy-naïve, 92 
measurable MM. It was hypothesized that the post-radiation administration of 93 
temozolomide might provide a clinical benefit over RT as sole treatment. 94 
 95 
 96 
Material and methods 97 
 98 
 5 
 99 
Entry requirement 100 
Dogs with newly diagnosed or recurrent, histologically confirmed MM of any clinical 101 
stage, for which surgery was either not feasible or refused by the owners, were 102 
eligible for recruitment. Malignant melanomas included tumors arising in the oral 103 
cavity, muco-cutaneous junctions, digit, and footpad,4,18-20 or in any other anatomic 104 
site having metastasis at presentation or high Ki-67 index (including >19.5 for oral 105 
sites, and ≥15 for cutaneous sites, as previously described).21,22 106 
Work-up for all dogs included physical examination, total body computed tomography 107 
(TBCT), tumor measurement, blood cell count (CBC) with white cell differential and 108 
biochemistry, fine-needle aspirate of regional lymph nodes (including CT-guided 109 
aspiration of retro-pharyngeal nodes) regardless of their size, and fine-needle 110 
aspirate of any suspicious lesion to confirm or rule out metastasis.  111 
All dogs were staged accordingly to the WHO clinical staging system.23,24 For dogs 112 
undergoing chemotherapy, additional entry requirements included full recovery from 113 
RT-related acute side effects, presence of adequate organ function defined as 114 
follows: absolute neutrophil count >1500/µl, platelets >100 000/µl, creatinine level <2 115 
mg/dl, and transaminases, bilirubin, alkaline phosphatase <1.5 upper limit of normal, 116 
and administration of at least 1 cycle of temozolomide. 117 
Excluded from the study were dogs with any other malignancy or clinically significant 118 
comorbidity that would interfere with the study evaluation, as well as those who had 119 
received prior chemotherapy, immunotherapy and/or RT. For all dogs receiving 120 
temozolomide, owners’ written consent was obtained. 121 
 122 
Radiation therapy 123 
 6 
Radiation was given by a Clinac DMX or Clinac iX (Varian Medical Systems, Palo 124 
Alto, CA, USA). Depending on tumor size and location, the treatment planning was 125 
performed on the basis of hand calculation for electron plans, or of a three-126 
dimensional CT for photon plans. For treatment planning the Eclipse External Beam 127 
Planning system version 8.1 or 10.0 (Varian Oncology Systems, Palo Alto, CA, USA), 128 
respectively, was used, applying the pencil beam convolution- (version 8.6.14) or 129 
AAA-algorithm (10.0.28).  130 
For planning CT and daily treatment, patients were placed under general anesthesia, 131 
positioned in sternal recumbency, and immobilized in an individually shaped vacuum 132 
cushion (BlueBag BodyFix, Elekta AB, Stockholm, Sweden). Dogs with tumors in the 133 
head area were additionally immobilized with a custom-made bite block.25 134 
The GTV (gross tumor volume) was delineated using co-registered or in parallel 135 
viewed contrast enhanced CT images, and CTV (clinical target volume), accounting 136 
for subclinical microscopic disease extension (local microscopic disease as well as 137 
regional lymph nodes), was defined. The CTV-margin was extended three-138 
dimensionally by 2 (for image-guided treatment) or 4 mm to define the planning target 139 
volume (PTV), accounting for internal physiologic movements, patient motion, and 140 
setup uncertainties. Organs at risk were segmented (eyes, lenses).  141 
The prescribed dose was 30 Gy, delivered in 5 bi-weekly fractions of 6 Gy to the 142 
ICRU reference point. The recommendations for specifying dose and volumes as 143 
proposed in Reports 50 and 62 of the ICRU26,27 were applied and variation up to +/- 144 
7.5% within PTV was considered acceptable. Treatment was performed isocentrically 145 
with bolus and wedges to ensure dose homogeneity.  146 
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Radiation-related toxicity was graded according to the Veterinary Radiation Therapy 147 
Oncology Group (VRTOG) scheme at each treatment, 2 weeks post completion, and 148 
monthly thereafter.28 149 
 150 
Chemotherapy 151 
Adjuvant chemotherapy was offered to all dogs. If owners rejected adjuvant 152 
treatment, dogs were included in Group 1. Dogs whose owners wished to pursue 153 
temozolomide were included in Group 2. 154 
Dogs were scheduled to start chemotherapy 2 weeks after the end of RT. 155 
Temozolomide (Temozolomide capsules 20 mg, Teva, Nerviano, Italy) was 156 
administered orally once daily for 5 consecutive days at a dose of 60 mg/m2. As 157 
temozolomide in Italy only comes as 5-mg and 20-mg capsules, the dose was 158 
administered to the nearest 5 mg. Treatment cycles were repeated every 28 days for 159 
4 cycles.  160 
If there was evidence of tumor shrinkage or stable disease (SD) at the end of the first 161 
2 cycles, dogs continued on to the next 2 cycles. If at any time there was evidence of 162 
disease progression or toxicity, temozolomide was discontinued and other options 163 
were discussed with the owners. 164 
All dogs were given prophylactic 25 mg kg-1 BID oral clavulanate-potentiated 165 
amoxicillin (Synulox tablets 500 mg, Pfizer, Rome, Italy) for 7 days after each of the 166 
first 2 treatments, and only if needed thereafter. Standard antiemetic therapy with oral 167 
2 mg kg-1 maropitant (Cerenia tablets 60 mg, Pfizer, Rome, Italy) was administered if 168 
necessary. 169 
Toxicity resulting from temozolomide was assessed based on the dog history, 170 
physical examination and CBC before the beginning of each next cycle and 10 days 171 
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after the administration, as reported by the Veterinary Co-operative Oncology 172 
Group.29 In case of grade 2 toxicities, therapy was delayed for 1 week until < grade 2, 173 
then restarted at the same dose. Conversely, the dose was reduced by 25% of the 174 
starting dose when grade 3 or 4 hematological or non-hematological toxicity 175 
occurred.  176 
 177 
Treatment response 178 
In either Group, tumor response was evaluated monthly by physical examination, 179 
chest x-ray, TBCT, or other diagnostic tests (including fine-needle aspiration of the 180 
regional lymph nodes), as appropriate. Standard Response Evaluation Criteria In 181 
Solid Tumors (RECIST) were used for response.30 182 
In particular, for dogs with oral melanoma (regardless of clinical stage) or melanoma 183 
at any site with distant metastasis, a TBCT was repeated at the end of RT. For 184 
melanoma arising at other anatomical sites without distant metastasis, dimensions of 185 
the primary tumor were manually measured, and distant metastasis were ruled out by 186 
thoracic radiographs and abdominal ultrasound.  187 
Complete remission was defined as the disappearance of all target lesions. Partial 188 
response (PR) was defined as a reduction of at least 30% in the sum of diameters of 189 
target lesions from baseline. Stable disease (SD) was defined as < 30% decrease or 190 
>20% increase in sum of diameters of target lesions from smallest sum while on 191 
treatment. Progressive disease (PD) was defined as an increase in the sum of 192 
diameters of target lesions by at least 20% over the size present at entry on study, or 193 
the appearance of new lesions. Responses were required to last for at least 28 days. 194 
Once PD was documented, rescue therapy of any kind was allowed. 195 
 196 
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 197 
Statistical analysis 198 
Dogs in Group 1 were assessed for response and toxicity if they completed the RT 199 
protocol, while those in Group 2 if they had received at least one cycle of treatment.  200 
In both groups, the overall response rate was defined as the number of dogs 201 
achieving CR or PR, compared with the total number of dogs treated. When 202 
considering the efficacy of RT, local disease was measured to assess degree of 203 
response. When considering the effect of temozolomide, both local and distant 204 
disease was measured. 205 
TTP was calculated from the date of initiation of treatment to the first progression of 206 
the disease (local and/or distant, depending on the treatment arm). TTP was 207 
censored for dogs without evidence of PD when lost to follow-up or at death. Dogs 208 
that died due to disease-related factors without having previously documentation of 209 
PD were considered as an event at the estimation of TTP.  210 
Survival time was calculated from the date of initiation of treatment to the date of 211 
death or day of last follow-up. Survival was censored for dogs alive at study’s end, 212 
dogs lost to follow-up, and dogs with a cause of death unrelated to MM or therapy for 213 
MM. If the cause of death was not known, death was attributed to MM. 214 
Fisher exact test was used to compare dogs’ characteristics at baseline, treatment 215 
response and toxicity. The Kaplan–Meier method was used to calculate TTP and OS 216 
curves, while the log-rank test was used to compare time to event distributions. The 217 
analysis was made on an intent-to-treat basis. A p-value of < 0.05 was considered 218 
significant for all analysis. All analyses were performed with a standard statistical 219 
software (GraphPad Prism, GraphPad La Jolla, CA, USA). 220 
 221 
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 222 
Results 223 
 224 
Dogs and tumor characteristics 225 
Between July 2009 and November 2013, 27 dogs met the inclusion criteria and were 226 
enrolled at 2 centers (Centro Oncologico Veterinario, Sasso Marconi, Italy, and 227 
Division of Radiation Oncology, Vetsuisse-Faculty, Zurich, Switzerland). Of those, 15 228 
dogs were treated with RT (Group 1) and 12 dogs were irradiated and subsequently 229 
treated with temozolomide (Group 2). 230 
 231 
In Group 1, there were 4 mixed-breed dogs and one each of the following: Great 232 
Dane, English Cocker Spaniel, Pug, Rottweiler, Dachshund, Pekingese, Italian 233 
Bracco, Poodle, Border collie, Chow Chow and Viszla. There were 8 males (of which 234 
3 castrated), and 7 spayed females. Median age was 13 years (range, 8 to 14 years), 235 
and median weight was 22 kg (range, 5.5 to 60.2 kg).  236 
MM location included mandible (n=6), maxilla (n=5), and one each of the following: 237 
eyelid, nasal planum, axilla, and footpad. Overall, 1 had stage I disease, 1 had stage 238 
II disease, 10 had stage III disease, and 3 had stage IV disease. Metastatic location 239 
for dogs with oral melanoma was as follows: bilateral mandibular lymph nodes (n=2), 240 
ipsilateral mandibular lymph node (n=1), lungs (n=1), ipsilateral mandibular and 241 
retropharyngeal lymph nodes and lungs (n=1). The dog with a palpebral MM had 242 
metastatic ipsilateral mandibular lymph node, the dog with nasal MM had metastatic 243 
bilateral mandibular lymph nodes, and the dog with MM on his paw had metastatic 244 
ipsilateral cervical lymph node. The dog with stage I oral melanoma and the one with 245 
 11 
stage III cutaneous melanoma had a Ki67 index of 23% and 18%, respectively, and 246 
were both considered to be biologically aggressive. 247 
Two dogs had previous surgeries and presented with macroscopic recurrent disease. 248 
Thirteen dogs had inoperable MM at first presentation. 249 
 250 
In Group 2, there were 4 mixed-breed dogs, and one each of the following: Dogue de 251 
Bordeaux, Schnauzer, Hound, Labrador retriever, Spitz, Golden retriever, German 252 
shepherd and Dachshund. There were 9 males (of which 2 castrated) and 3 females 253 
(of which one spayed). Median age was 13 years (range, 7 to 15 years), and median 254 
weight was 29 kg (range, 3.5 to 44.5 kg). 255 
MM location included maxilla (n=7), mandible (n=2), eyelid (n=1), digit (n=1), and 256 
mucosal aspect of the lip (n=1). Overall, 1 dog had stage I disease, 2 had stage II 257 
disease, 8 had stage III disease, and 1 had stage IV disease. Metastatic location for 258 
dogs with oral melanoma was as follows: ipsilateral mandibular lymph node (n=2), 259 
bilateral mandibular lymph nodes (n=1), and ipsilateral mandibular lymph node and 260 
lungs (n=1). The dog with a palpebral MM had metastatic bilateral mandibular lymph 261 
nodes, and the dog with a digit melanoma had a metastatic ipsilateral prescapular 262 
lymph node. The dog with stage I oral melanoma had a Ki67 index of 28%, and was 263 
therefore included. 264 
Seven dogs had previous surgeries, whereas for 5 dogs presented with naïve 265 
disease.   266 
Dogs’ demographics were similar for each treatment group (Table 1). There were no 267 
significant differences in breed, age, sex, disease site, and distribution of stage at 268 
baseline between the treatment groups. Rates of previous surgeries were statistically 269 
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different across groups, due to the higher percentage of dogs undergoing previous 270 
excision in Group 2 compared to Group 1 (p = 0.013). 271 
 272 
 273 
Treatment and toxicity 274 
All dogs in Group 1 completed the planned RT protocol within 2.5 weeks. Toxicity 275 
occurred in 7 dogs and was limited to grade 1-2 mucositis, which resolved 276 
uneventfully within 3 weeks after the end of RT. 277 
Similarly, all dogs in Group 2 completed the planned RT protocol within 2.5 weeks. 278 
Toxicity occurred in 4 dogs and was limited to grade 1-2 mucositis. Two to 3 weeks 279 
after RT, this group of dogs received 1 to 4 (median, 4) cycles of temozolomide, with 280 
6 (50%) dogs receiving 4 cycles, 3 (25%) receiving 3 cycles, 2 (16.7%) receiving 2 281 
cycles, and 1 (8.3%) dog receiving 1 cycle only. Reasons for not completing the 282 
planned 4 cycles were PD (n=4), financial concern (n=1) and melanoma-unrelated 283 
death (n=1). Chemotherapy was well tolerated, resulting in no dose reduction. Grade 284 
1 gastrointestinal toxicity consisting of nausea and loss of appetite occurred in 4 285 
(33.3%) dogs after the first cycle. No dogs stopped treatment because of toxicity, and 286 
no dog died due to complications of chemotherapy.  287 
 288 
Response rate and time to progression 289 
The primary melanomas from 13 dogs in Group 1 responded to RT, with an overall 290 
local response rate of 86.7% and a median TTP of 110 days (range, 60 to 798 days; 291 
95% CI 65-155). Among responders, 3 dogs obtained CR for 124, 174 and 798 days, 292 
and 10 dogs achieved PR with a median duration of 95 days (range, 29 to 236 days). 293 
Two dogs had SD for 34 and 59 days, respectively. At data analysis closure, all dogs 294 
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had documented disease progression: 8 dogs had local failure, 3 had distant failure, 295 
and 4 dogs had local and distant failure. Four dogs in this group developed distant 296 
metastasis during the study period: 2 of them developed lung metastasis, 1 dog 297 
developed pulmonary and brain metastasis, and 1 dog developed brain metastasis 298 
after a median of 87 days from the initial presentation (range, 39 to 165 days). 299 
Regarding Group 2, at the end of RT and before starting chemotherapy, 2 dogs 300 
obtained CR, and 8 dogs obtained PR, with an overall local response rate to RT of 301 
83.3%. Two dogs obtained SD. When considering the effect of temozolomide, the 302 
overall (local and distant) response rate was of 81.1% and the median TTP was 205 303 
days (range, 55 to 1010 days; 95% CI 141.9-242.1). Two dogs obtained CR for 1010 304 
and 205 days, 8 dogs obtained PR for a median of 138 days (range, 55 to 181 days), 305 
and 2 dogs had SD for 78 and 143 days.  306 
At data analysis closure, 6 dogs had documented disease progression: 1 had local 307 
failure, and 5 had distant failure. During the study period, 4 dogs developed distant 308 
metastasis to lung (n=3) and bone (n=1) after 55, 78, 88 and 181 days.  309 
Treatment response rate and distant metastatic rate were not significantly different 310 
between groups (Table 2). However, dogs in Group 2 had a significantly longer TTP 311 
than dogs in Group 1 (p = 0.046; Fig. 1). Also, 6 (50%) of the dogs in Group 2 312 
experienced disease progression, compared with 15 (100%) dogs in Group 1 (p = 313 
0.001). 314 
 315 
Rescue treatment 316 
Overall, 3 dogs received rescue treatment after PD was documented. In Group 1, 317 
one dog underwent surgical excision after local failure and died after 196 days from 318 
initial presentation, and 1 dog received a different investigational cytotoxic therapy 319 
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and died after 165 days. In Group 2, 1 dog was irradiated again after local failure, 320 
and was still alive 596 days from initial presentation. 321 
 322 
Survival 323 
At the end of the study, 14 dogs in Group 1 were dead and 1 (with stage I disease) 324 
was still alive after 187 days. Among the dead dogs, 2 died for tumor-unrelated 325 
disease; however in both dogs the melanoma was locally progressing.  In the 326 
remaining dogs, death was attributable to local failure (n=5), local and distant failure 327 
(n=4), and distant failure (n=3). In Group 2, 8 dogs had died and 4 (3 with stage III 328 
disease, and 1 with stage II disease) were still alive with a median follow-up of 405 329 
days. Three dogs died for tumor-unrelated causes (2 with PR and 1 with SD). In the 330 
remaining 5 dogs, death was attributable to distant failure. Survival did not differ 331 
significantly between the 2 groups (192 days for Group 1 versus 401 days for Group 332 
2, p = 0.093; Table 2). 333 
 334 
 335 
Discussion 336 
 337 
Advanced melanoma represents one of the most treatment-refractory malignancies 338 
and its treatment remains unsatisfactory. Despite decades of research, there have 339 
been no new drugs advisable for use in canine melanoma, and a consensus on a 340 
standard first-line treatment has yet to be established.  341 
 342 
The median survival for dogs with surgically resected stage II-III oral melanoma is 343 
only 3–12 months with an estimated 1-year survival rate of approximately 20%.31,32 344 
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Regardless of the clinical stage, a threshold for Ki67 above 19.5 predicted 345 
melanoma-related death by 1-year post diagnosis, and should therefore be 346 
considered as a negative prognostic factor.21 For cutaneous MM, a high Ki67 value 347 
has also been associated with shorter survival.22 348 
Unfortunately, these survival figures have not changed in more than a decade of 349 
clinical studies, mostly due to the unsatisfactory efficacy of systemic 350 
chemotherapy,6,33,34 and even to newer treatment options, such as gene therapy.35,36 351 
Equally important, the role of new treatment modalities (e.g. immunotherapy) in 352 
influencing outcome of MM trials has been conflicting, and promising results of 353 
single-institution studies have repeatedly failed to survive the scrutiny of subsequent 354 
studies.9,37 Therefore, loco-regional therapy with palliative intent remains the current 355 
mainstay of treatment.  356 
 357 
The results of this study showed that dogs with measurable MM that received post-358 
radiation temozolomide might have a prolonged TTP compared with dogs undergoing 359 
RT only.  360 
On an intent-to-treat basis the overall response rates were similar for both treatments 361 
arms (81-86%), being in agreement with the previous literature documenting CR 362 
rates of 53-69% and PR rates of 25-30% in dogs receiving coarse fractionation RT 363 
schemes.34,38-41 However, dogs treated with post-RT temozolomide had a median 364 
TTP of 205 days compared to 110 days in dogs undergoing RT only, and this 365 
difference was statistically significant. Also, dogs receiving temozolomide had a 366 
significant lower local and distant failure rate compared with irradiated dogs (50% 367 
versus 100%, respectively).  368 
 369 
 16 
The median survival time in Group 1 and Group 2 of 192 and 401 days, respectively, 370 
is comparable to that reported in the literature describing RT with or without 371 
carboplatin.34,42 Although dogs receiving temozolomide lived longer that irradiated 372 
dogs (401 and 192 days, respectively), this difference only tended to be statistically 373 
significant. This result may be partly attributable to the small sample size and to the 374 
insufficient follow-up interval such that a survival advantage could not be discerned. 375 
Indeed, 4 dogs in Group 2 were still alive at data analysis closure, compared to 1 dog 376 
in Group 1. It may be possible that a longer follow-up might translate into a survival 377 
benefit as well. 378 
 379 
 380 
Many variables have been previously shown to have prognostic value in dogs with 381 
MM, including anatomical site, tumor size, bone lysis, and clinical stage.4,19,34 To be 382 
representative of the general melanoma population, dogs with high-risk non-oral MM 383 
were included in this study. It was felt that these dogs had the potential to benefit 384 
from systemic chemotherapy because of the documented metastasis at initial 385 
presentation. The dogs in our study had comparable baseline characteristics 386 
between the treatment arms, demonstrating no imbalance in known prognostic 387 
factors. Dogs receiving temozolomide were more likely to have undergone previous 388 
surgery compared with irradiated dogs, and this difference was significant. This could 389 
be a random finding, or alternatively be due to a selection bias resulting in owners 390 
being more likely to pursue further treatment after already having agreed on multiple 391 
surgeries. 392 
In the present study, long-term survival did not occur, with the exception of 3 dogs 393 
achieving an initial CR in response to RT; 2 of them additionally received post-394 
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radiation temozolomide. All of them had high-risk features at diagnosis, including 395 
bilateral regional lymph nodes metastasis (n=2), and a T3 oral tumor (n=1). One of 396 
them died because of melanoma-unrelated causes after 826 days, and the 2 other 397 
dogs are still alive after 1041 and 635 days, one of them still being in durable first 398 
CR. Although we did not look statistically at this, it may be possible that achievement 399 
of CR after RT may translate into prolonged survival. 400 
 401 
Temozolomide, which is orally formulated, allows for outpatient treatment. This is 402 
particularly desirable for dogs with a tended short life expectancy. In this case series, 403 
treatment was generally well tolerated; the reported adverse events were consistent 404 
with prior RT reports, and no new clinically significant temozolomide safety issues 405 
were identified in the present study. Nausea and loss of appetite were reported in the 406 
temozolomide group, which is consistent with the prescribing information for this 407 
agent.43 Hematologic toxicities were not an issue with temozolomide. 408 
The toxicity profile of temozolomide in this trial therefore appears to be manageable. 409 
However, it is possible that the acceptable tolerability of temozolomide in this study 410 
may be a consequence of underdosing and could therefore explain the observed 411 
nonsignificant metastatic rate differences between groups. Indeed, the number of 412 
dogs that developed distant metastasis in Group 1 (4 of 15, 26.7%) was comparable 413 
to Group 2 (4 of 12, 33.3%),. Notably, no dogs in Group 2 developed symptomatic 414 
cerebral metastasis, in contrast to Group 1 (2 of 4, 50%), suggesting that 415 
temozolomide may prevent the occurrence of metastasis to the brain. In dogs, 416 
temozolomide has only been used in combination with doxorubicin to treat 417 
lymphoma,17 and no Phase I dose-escalation clinical trials have been conducted so 418 
far. In this previously published paper, the starting dose of oral temozolomide was 60 419 
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mg/m2 administered every 24 hours for 5 consecutive days. This dose was elected 420 
on the basis of available toxicology data for dogs,44 the minimum risk of side effects 421 
when administered at the same dose in humans, and the convenience of 422 
administration given the currently available capsule sizes. Temozolomide was 423 
escalated up to a median dose of approximately 90 mg/m2 with various grades of 424 
hematological, gastrointestinal and renal toxicity. Of note, the authors reported no 425 
significant association between temozolomide dose and duration of response.17 426 
Based on the above, in the current study the dose of 60 mg/m2 was elected. 427 
Temozolomide is considered to be a radiosensitizing agent for certain tumor 428 
types,13,16 and at present there are no studies in veterinary medicine exploring the 429 
possible overlapping toxicity profile of this drug given after RT. Furthermore, since 430 
chemotherapy was intended to be palliative, it was decided to use a dose that was 431 
considered to be safe. Indeed, treatment was well tolerated, with gastrointestinal 432 
toxicity no higher than grade 1 reported as the only adverse event. It is therefore 433 
likely that the dose of temozolomide used here was overcautious with regard to 434 
toxicity and that the maximal dosage range was not explored in full. In people, it has 435 
been shown that extended dosing regimens allow for administration of a higher 436 
cumulative dose per cycle, thereby depleting O6-methylguanine-DNA 437 
methyltransferase and consequently enhancing cytotoxic activity.45 438 
 439 
The prophylactic use of antibiotics in patients with cancer undergoing chemotherapy is 440 
controversial.46,47 However, it is well documented that infections are significant 441 
causes of morbidity and mortality among immunocompromised patients. Oral and 442 
digital tumors are often ulcerated, providing a source of microbial infections. 443 
Furthermore, RT-related side effects also remain a major source of illness, as 444 
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radiation injury decreases host defenses.48 Although temozolomide was not 445 
associated with significant hematological toxicity, prophylactic antibiotics were 446 
administered during the first cycles of chemotherapy aiming at reducing the risk of 447 
infection associated with cancer itself, RT or chemotherapy-related neutropenia.  448 
This study has some limitations. Although it was attempted to have a homogeneous 449 
population of high-risk tumors, dogs with melanoma arising at different anatomic sites 450 
and of different clinical stages were enrolled, possibly having increased the biologic 451 
variability in this study. Also, because of the small sample size included in the 452 
present study, it is not possible to know whether TTP and survival time among a 453 
larger number of dogs treated in a similar fashion would be similar. Another limitation 454 
of this study is the lack of randomization. It may be possible that pet owners whose 455 
dogs had a less advanced clinical stage were more motivated to participate in a 456 
clinical trial. Finally, methylation of MGMT has been associated with greater benefit 457 
from temozolomide that unmethylated MGMT in people with unresectable 458 
glioblastoma.49 Additional molecular, biological or host factors need to be identified in 459 
dogs to predict tumor response to chemotherapy. 460 
In conclusion, coarse fractionated RT followed by temozolomide may improve TTP 461 
compared with RT alone in dogs with chemotherapy-naïve, measurable MM. The 462 
good safety profile, and ease of administration suggest that temozolomide could play 463 
an important role in the future management of this disease. Further clinical research 464 
is warranted to refine the choice of temozolomide dose. 465 
 466 
 467 
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Figure legend 647 
Fig 1. Kaplan–Meier curve depicting TTP of dogs treated with RT (blue line) and with 648 
RT and temozolomide (green line).  649 
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